OBJECTIVES: Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections. METHODS: A recent (2005-06) collection of bacterial isolates originating from patients with bloodstream, respiratory tract, and skin and skin structure infections in US medical centres was evaluated by reference broth microdilution methods against omiganan and comparator agents. RESULTS: All tested gram-positive (390) and -negative (167) isolates were inhibited by < or = 128 and < or = 1024 mg/L, respectively, of omiganan. The agent was the most active against coagulase-negative staphylococci (range 1-8 mg/L; MIC(50/90), 4 mg/L) and inhibited all Staphylococcus aureus at < or = 32 mg/L (MIC(50/90), 16 mg/L). Omiganan was 16-fold more active against Enterococcus faecium than Enterococcus faecalis (MIC(50/90) results, 4/8 versus 64/128 mg/L, respectively). MIC ranges and MIC(50) potencies were unaffected by methicillin resistance in staphylococci, vancomycin resistance in enterococci, and penicillin resistance in streptococci. Omiganan potency was also unaffected by extended-spectrum beta-lactamase (ESBL) production in Escherichia coli when compared with wild-type strains (MIC(50) values 32 mg/L), although a 4-fold increase was noted among ESBL-positive Klebsiella spp. (128 versus 32 mg/L, respectively). Wild-type Enterobacter spp. displayed higher omiganan MIC(50/90) results (64/512 mg/L) compared with AmpC-hyperproducing strains (32/64 mg/L). Carbapenem-susceptible and -resistant P. aeruginosa strains exhibited omiganan MIC(50/90) values of 128/256 mg/L. CONCLUSIONS: At a 1% (10 000 mg/L) topical gel formulation, omiganan can be expected to inhibit all clinically relevant bacterial species producing catheter-associated infections (all MIC values, < or = 1024 mg/L), including those with antimicrobial-resistant phenotypes.

中文翻译：

---

测试了奥米加仑五盐酸盐的抗菌活性，该抗菌剂对通常与导管相关的感染负责的现代细菌病原体。

目的：五聚盐酸奥米加南（Omiganan pentahydrochloride）是一种抗菌肽，具有广泛的抗菌谱，包括酵母，目前正在开发中，可作为预防导管相关感染的局部用药。我们评估了omiganan对通常与此类感染相关的病原体的光谱和效力。方法：通过参考肉汤微量稀释法对含氧量和比较剂进行评估，最近（2005-06）在美国医学中心收集了来自患有血液，呼吸道以及皮肤和皮肤结构感染的患者的细菌分离株。结果：所有测试的革兰氏阳性菌（390）和-阴性菌（167）分别被≤或= 128 mg / L和≤或= 1024 mg / L的欧米茄聚糖抑制。该药物对凝固酶阴性葡萄球菌的活性最高（范围为1-8 mg / L；MIC（50/90），4 mg / L）并以<或= 32 mg / L（MIC（50/90），16 mg / L）抑制所有金黄色葡萄球菌。与粪肠球菌相比，Omiganan对粪肠球菌的活性高16倍（MIC（50/90）结果，分别为4/8和64/128 mg / L）。MIC范围和MIC（50）的效力不受葡萄球菌中的甲氧西林耐药性，肠球菌中的万古霉素耐药性和链球菌中的青霉素耐药性的影响。与野生型菌株（MIC（50）值为32 mg / L）相比，大肠埃希氏大肠杆菌中的广谱β-内酰胺酶（ESBL）产量也不受Omiganan效力的影响，尽管在ESBL阳性患者中发现其增加了4倍克雷伯菌属。（分别为128和32 mg / L）。野生型肠杆菌属。与高产AmpC菌株（32/64 mg / L）相比，显示出更高的omiganan MIC（50/90）结果（64/512 mg / L）。对碳青霉烯敏感和耐药的铜绿假单胞菌菌株显示的含氮量MIC（50/90）值为128/256 mg / L。结论：以1％（10000 mg / L）的局部凝胶制剂使用，奥米加南有望抑制所有临床相关细菌产生导管相关感染（所有MIC值≤1024 mg / L），包括那些抗菌素耐药表型。